Simcere Pharmaceutical Group Limited (2096.HK) is a pharmaceutical company driven by innovative R&D. We are committed to "providing today's patients with medicines of the future" across the following core therapeutic areas: oncology, central nervous system, autoimmunity and anti-infection. Furthermore, we are also actively expanding our presence in disease areas with significant clinical needs in the future.
Our industry-leading capabilities and commitment to synergistic innovation have also enabled various strategic collaborations and we are seen as partner of choice by innovative biopharmaceutical companies, medical institutes, and research teams in China and globally.

Milestones

1995
2001
2003
2006
2007
2013
2015
2018
2019
2020
2021
2022
2023

established Jiangsu Simcere, engaging in the sales, marketing and distribution of pharmaceuticals
cquired a controlling interest in Hainan Simcere and manufacturing capabilities of pharmaceuticals, built our own research and development team
acquired the entire equity interest in Simcere Dongyuan, established postdoctoral research station (博士后科研工作站)
acquired a controlling interest in Shandong Simcere
became the first bio and chemical pharmaceutical company in China to be listed on the NYSE
completed the privatization
established the National Key Laboratory of Translational Medicine and Innovative Pharmaceuticals (转化医学与创新药物国家重点实验室) approved by the Ministry of Science and Technology
Shanghai R&D center established
Boston Innovation Center
Orencia^® approved
Sanbexin^® approved
Listed on the Hong Kong Stock Exchange
Enweida^® approved
Beijing Innovation Center
Cosela^® approved
Xiannuoxin^®approved

1995
established Jiangsu Simcere, engaging in the sales, marketing and distribution of pharmaceuticals
2001
cquired a controlling interest in Hainan Simcere and manufacturing capabilities of pharmaceuticals, built our own research and development team
2003
acquired the entire equity interest in Simcere Dongyuan, established postdoctoral research station (博士后科研工作站)
2006
acquired a controlling interest in Shandong Simcere
2007
became the first bio and chemical pharmaceutical company in China to be listed on the NYSE
2013
completed the privatization
2015
established the National Key Laboratory of Translational Medicine and Innovative Pharmaceuticals (转化医学与创新药物国家重点实验室) approved by the Ministry of Science and Technology
2018
Shanghai R&D center established
2019
Boston Innovation Center
2020
Orencia® approved
Sanbexin® approved
Listed on the Hong Kong Stock Exchange
2021
Enweida^® approved
Beijing Innovation Center
2022
Cosela^® approved
2023
Xiannuoxin^®approved

Management Team

: Ren Jinsheng

Chairman of the Board and
Chief Executive Officer

: Tang Renhong, PhD

Executive Director of Simcere
Chairman of the Board and CEO of Simcere Zaiming

: Wan Yushan

Executive Director and
Chief Financial Officer

: Wang Xi

Executive Director and Vice President

: Bijoyesh Mookerjee, MD

Chief Medical Officer, Oncology

: Zhou Gaobo

Chief Investment Officer

: Tamas Oravecz, PhD

Senior Vice President
CSO of Simcere, U.S.

: Andrew Zhu

Senior Vice President

: Danny Chen, PhD

Senior Vice President

: Kevin Oliver, PhD

Senior Vice President

: Song Wenjie

Senior Vice President of Simcere Zaiming

Mission

Providing Today’s Patients with Medicines of the Future

Core values

: PATIENT FIRST

: JOINT EFFORT

: INTEGRITY

: EXCELLENCE

Simcere CI

The name “Simcere” comes from the word “sincere”, which embodies our main principle of treating people with sincerity.
On the left side of our logo is Simcerer running against the wind, representing the spirit of unremitting endeavor and the encourage to pursue excellence.
The color green symbolizes life, health and vitality.

Milestones

Management Team

Ren Jinsheng

Tang Renhong, PhD

Wan Yushan

Wang Xi

Bijoyesh Mookerjee, MD

Zhou Gaobo

Tamas Oravecz, PhD

Andrew Zhu

Danny Chen, PhD

Kevin Oliver, PhD

Song Wenjie

Mission

Providing Today’s Patients with Medicines of the Future

Core values

Simcere CI